8-K ·Filed May 20, 2026

SUPN

SUPERNUS PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001356576-26-000025
8-K context-dependent: Items 2.03
Actionable Insight • Neutral

The $33.4M payment was a known contingent liability from the July 2025 CVR deal. Monitor the company's next quarterly cash position to assess whether this outflow pressures liquidity or R&D spending. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
SUPN ▼ -2.25% at T+60d
NEUTRAL call ✗ call lost -2.25% · α vs SPY -6.55% · entry $49.38 → $48.27
Entry anchored
May 20, 03:59 PM ET
via exchange tick
T+1d
-2.37%
call -2.37% · α -2.81%
$48.21
settled 4mo ago
T+5d
-5.12%
call -5.12% · α -6.72%
$46.85
settled 4mo ago
T+20d
-9.96%
call -9.96% · α -10.30%
$44.46
settled 4mo ago
T+60d
-2.25%
call -2.25% · α -6.55%
$48.27
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Supernus notified the CVR rights agent that Milestone 1 was achieved on March 18, 2026, triggering a $0.50-per-CVR cash payment totaling approximately $33.4 million. The company will deposit funds with the rights agent within 20 business days. This is a pre-existing contractual obligation from the July 2025 CVR Agreement, not new debt or a surprise liability.

Key Facts

  • Milestone 1 under the CVR Agreement achieved on March 18, 2026
  • Payment of $0.50 per CVR, aggregate approximately $33.4 million
  • Funds to be deposited with rights agent within 20 business days of May 17, 2026
  • Obligation stems from CVR Agreement dated July 30, 2025

Financial Impact

Cash outflow of approximately $33.4 million (about 1.2% of $2.8B market cap)

cashliabilities

Risk Factors

  • Cash outflow reduces balance sheet flexibility by ~$33M
  • Future CVR milestones could trigger additional payments

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001356576-26-000025
Document: 0001356576-26-000025-index-headers.html0001356576-26-000025
Document: 0001356576-26-000025-index.html0001356576-26-000025
Document: 0001356576-26-000025.txt0001356576-26-000025
20 reports for SUPN
Performance horizon
75% Hit rate 6 of 8 directional calls best @ T+1▲ +8.46%Aug 3, 2026
Filters
Rows
Reports for SUPN — sortable, filterable
TypeNow
Sep 11, 2026
20d ago
DEFM14A
MIXED ★ 7/10
$41.49 $42.78▲ +3.11%▲ +3.00%$42.60 (+2.68%)
Aug 3, 2026
8w ago
DEFA14A / 425
BULLISH ★ 7/10
$43.25 $46.88▲ +8.39%▲ +8.49%$42.60 (−1.50%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$43.25 $46.88▲ +8.39%▲ +8.49%$42.60 (−1.50%)
Aug 3, 2026
8w ago
DEFA14A / 425
BULLISH ★ 8/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
8-K
MIXED ★ 7/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Aug 3, 2026
8w ago
DEFA14A / 425 / 8-K
BULLISH ★ 8/10
$46.00 $47.07▲ +2.33%▲ +0.30%$42.60 (−7.39%)
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$47.19 $45.61▼ −3.35%▼ −3.82%$42.60 (−9.73%)
Jul 22, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$47.19 $45.61▼ −3.35%▼ −3.82%$42.60 (−9.73%)
Jul 20, 2026
10w ago
Court Ruling
NEUTRAL ★ 3/10
$47.42 $46.20▼ −2.57%▼ −2.15%$42.60 (−10.16%)
Showing 10 of 20

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access